Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Rating of “Hold” by Brokerages

Carisma Therapeutics, Inc. (NASDAQ:CARM) has been given an average recommendation of “Hold” by the seven analysts that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $4.94.

A number of research analysts recently commented on the company. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 30th. D. Boral Capital dropped their target price on shares of Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, December 9th. Baird R W lowered shares of Carisma Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. HC Wainwright reissued a “neutral” rating on shares of Carisma Therapeutics in a research note on Monday, December 16th. Finally, Evercore ISI restated an “in-line” rating and set a $0.70 target price (down from $4.00) on shares of Carisma Therapeutics in a research note on Wednesday, December 11th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Carisma Therapeutics in the second quarter worth approximately $40,000. Wexford Capital LP raised its holdings in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares during the last quarter. Finally, Barclays PLC lifted its position in shares of Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock worth $539,000 after purchasing an additional 549,290 shares during the period. 44.27% of the stock is owned by institutional investors and hedge funds.

Carisma Therapeutics Stock Down 0.6 %

CARM stock opened at $0.47 on Monday. Carisma Therapeutics has a fifty-two week low of $0.38 and a fifty-two week high of $2.94. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.23 and a quick ratio of 3.23. The stock has a market capitalization of $19.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.44. The business’s fifty day moving average price is $0.70 and its two-hundred day moving average price is $0.94.

Carisma Therapeutics (NASDAQ:CARM) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). The firm had revenue of $3.39 million during the quarter. Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. On average, equities analysts anticipate that Carisma Therapeutics will post -1.32 earnings per share for the current year.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.